Rodger Novak - Crispr Therapeutics CEO, Co-Founder, Director
| CRSP Stock | USD 55.07 1.26 2.34% |
CEO
Dr. Rodger Novak, M.D., was Chairman of the Board of Directors, President and Founder of CRISPR Therapeutics Ltd since December 21, 2017. He was President, CoFounder, Director of the Company from December 1, 2017. He is an experienced pharmaceutical and biotechnology executive and former University Professor at the Vienna Biocenter in Austria. In his most recent position, he was Global Head, AntiInfectives Research Development at Sanofi, where he was responsible for small molecule and biologics RD, including early drug discovery and clinical development. Before that he was a founder of Nabriva Therapeutics and served as its Chief Operating Officer for almost six years. He started his pharmaceutical career at Sandoz, where he was appointed as the deputy Head of the Antibiotic Research Institute. He received his M.D. from the Philipps University in Marburg, Germany in 1993 and his foreign medical license for the United States in 1994. He was a postdoctoral fellow at The Rockefeller University, St. Jude Childrens Research Hospital and the Skirball Institute NYU Medical Center. During his academic career he authored numerous publications, among them articles in Nature, Nature Medicine and Molecular Cell. He is coinventor of five patents. since 2017.
| Age | 48 |
| Tenure | 7 years |
| Professional Marks | Ph.D |
| Phone | 41 41 561 32 77 |
| Web | https://www.crisprtx.com |
Crispr Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0622) % which means that it has lost $0.0622 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0817) %, meaning that it created substantial loss on money invested by shareholders. Crispr Therapeutics' management efficiency ratios could be used to measure how well Crispr Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | CEO Age | ||
| Douglas Ingram | Sarepta Therapeutics | 55 | |
| Gilmore MD | Editas Medicine | 59 | |
| John MD | Intellia Therapeutics | 67 | |
| Robert Foster | Hepion Pharmaceuticals | N/A | |
| Katrine Bosley | Editas Medicine | 50 | |
| Leonard Schleifer | Regeneron Pharmaceuticals | 65 | |
| Douglas Esq | Sarepta Therapeutics | 61 | |
| Geoffrey MacKay | AVROBIO | N/A | |
| John Wolchko | Fate Therapeutics | 47 | |
| Lars Joergensen | Novo Nordisk AS | 54 | |
| Lars Soerensen | Novo Nordisk AS | 60 | |
| Scott Wolchko | Fate Therapeutics | 54 | |
| Nessan Bermingham | Intellia Therapeutics | 51 | |
| Geoff MacKay | AVROBIO | 50 | |
| Gilmore ONeill | Editas Medicine | 60 | |
| Lars Jorgensen | Novo Nordisk AS | 58 | |
Management Performance
| Return On Equity | -0.0817 | ||||
| Return On Asset | -0.0622 |
Crispr Therapeutics Leadership Team
Elected by the shareholders, the Crispr Therapeutics' board of directors comprises two types of representatives: Crispr Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Crispr. The board's role is to monitor Crispr Therapeutics' management team and ensure that shareholders' interests are well served. Crispr Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Crispr Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Samarth Kulkarni, Chief Business Officer | ||
| Simeon George, Independent Director | ||
| Ali Behbahani, Independent Director | ||
| Tyler DylanHyde, Chief Legal Officer | ||
| Marc Becker, CFO | ||
| Jim Kasinger, General Counsel, Secretary to the Board of Directors | ||
| Susan Kim, Vice Relations | ||
| Anthony Coles, Independent Chairman of the Board | ||
| Thomas Woiwode, Independent Director | ||
| Rodger MD, Chairman Founder | ||
| Rodger Novak, CEO, Co-Founder, Director | ||
| Tom Woiwode, Independent Director | ||
| Matthew MD, Scientific Member | ||
| Stephen Kennedy, Head Operations | ||
| Kala Subramanian, Senior Vice President - Strategic Development and Operations | ||
| Michael Esposito, Acting Principal Accounting Officer | ||
| Tony Ho, Head of Research and Development | ||
| Jon Terrett, Head of Immuno-Oncology Research and Translation | ||
| Shaun Foy, Founder | ||
| Sven Lundberg, Chief Scientific Officer | ||
| Bradley Bolzon, Independent Director | ||
| Kurt Emster, Independent Director | ||
| Craig Mello, Scientific Member | ||
| Lawrence Klein, Chief Officer | ||
| Chad Cowan, Scientific Founder | ||
| Daniel Anderson, Scientific Member | ||
| Emmanuelle Charpentier, CoFounder Member | ||
| Raju Prasad, Chief Officer | ||
| James Kasinger, General Counsel, Secretary to the Board of Directors | ||
| Brendan MBA, CFO VP | ||
| Pablo Cagnoni, Independent Director | ||
| MD FACP, Chief Officer | ||
| Megan Menner, Senior Vice President of Human Resources | ||
| Chris Brinzey, Investor Relations Contact Officer |
Crispr Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Crispr Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0817 | ||||
| Return On Asset | -0.0622 | ||||
| Profit Margin | (0.41) % | ||||
| Operating Margin | 0.35 % | ||||
| Current Valuation | 2.8 B | ||||
| Shares Outstanding | 84.88 M | ||||
| Shares Owned By Insiders | 1.86 % | ||||
| Shares Owned By Institutions | 78.00 % | ||||
| Number Of Shares Shorted | 14.74 M | ||||
| Price To Earning | 17.33 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Crispr Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Crispr Therapeutics' short interest history, or implied volatility extrapolated from Crispr Therapeutics options trading.
Pair Trading with Crispr Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Crispr Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Crispr Stock
| 0.78 | EVOK | Evoke Pharma | PairCorr |
Moving against Crispr Stock
| 0.7 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.63 | ELYM | Eliem Therapeutics Trending | PairCorr |
| 0.45 | DYAI | Dyadic International Financial Report 8th of May 2024 | PairCorr |
| 0.45 | IBIO | Ibio Inc | PairCorr |
The ability to find closely correlated positions to Crispr Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Crispr Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Crispr Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Crispr Therapeutics AG to buy it.
The correlation of Crispr Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Crispr Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Crispr Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Crispr Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Crispr Therapeutics AG. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Crispr Stock analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Crispr Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Crispr Therapeutics. If investors know Crispr will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Crispr Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Crispr Therapeutics is measured differently than its book value, which is the value of Crispr that is recorded on the company's balance sheet. Investors also form their own opinion of Crispr Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Crispr Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Crispr Therapeutics' market value can be influenced by many factors that don't directly affect Crispr Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Crispr Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Crispr Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Crispr Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.